Actelion's Uptravi Given Positive Opinion By CHMP
This article was originally published in Scrip
Executive Summary
Actelion Pharmaceuticals Ltd.'s orally active selective prostacyclin agonist Uptravi (selexipag) has been recommended for marketing in Europe for the treatment of pulmonary arterial hypertension by the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), just over a month after the product gained a marketing approval in the US.